Skip to main content
PROTEOME SCIENCES PLC logo

PROTEOME SCIENCES PLC — Investor Relations & Filings

Ticker · PRM ISIN · GB0003104196 LEI · 213800Q62ICXANKU2986 IL Professional, scientific and technical activities
Open in API
Filings indexed 279 across all filing types
Latest filing 2014-09-30 Share Issue/Capital Cha…
Country GB United Kingdom
Listing IL PRM

About PROTEOME SCIENCES PLC

https://www.proteomics.com/

Proteome Sciences PLC is a specialized Contract Research Organization (CRO) focused on applied proteomics and peptidomics. The company provides comprehensive mass spectrometry-based analytical services to support drug discovery, development, and biomarker identification for precision medicine. Its services cover the full workflow from sample preparation and proteome characterization to bioinformatics data interpretation and reporting, handling diverse biological samples. A key offering is its proprietary TMT® and TMTpro® isobaric tags, which the company invented, developed, and exclusively manufactures for multiplexed protein quantification. These reagents are distributed globally to the mass spectrometry community. The company serves the biopharmaceutical sector, operating under ISO 9001:2015 and Good Clinical Laboratory Practice (GCLP) standards for its targeted assays.

Recent filings

Filing Released Lang Actions
Blocklisting Interim Review
Share Issue/Capital Change Classification · 1% confidence The document is very short (1207 characters) and is explicitly marked with an 'RNS Number' (8442S), indicating it is a regulatory announcement from the London Stock Exchange's news service. The content details a 'Block Admission return' concerning share option plans and the number of shares not yet issued over a specific period (April 1, 2014, to September 30, 2014). This type of routine administrative update regarding share capital structure and listing compliance, especially when presented as a brief notice via RNS, fits best under the general 'Regulatory Filings' category, as it does not specifically match the criteria for Share Issue/Capital Change (SHA) which usually involves the actual issuance or buyback, or a specific dividend/director dealing notice. Given the context of an RNS number and the nature of the update, RNS is the most appropriate classification.
2014-09-30 English
Directorate Change
Board/Management Information Classification · 1% confidence The document explicitly starts with an 'RNS Number' and contains an announcement titled 'Appointment of new Finance Director'. This is a formal notification regarding a change in senior management personnel. According to the definitions, 'Board/Management Information' (Code: MANG) covers the 'Announcement of changes in the company's board of directors or senior management.' Although it is distributed via RNS, the specific content points directly to MANG, which is a more precise classification than the general RNS fallback.
2014-09-30 English
Half Yearly Report
Interim / Quarterly Report Classification · 1% confidence The document is an 'Unaudited Interim Results' report for the six months ended 30th June 2014. It contains detailed financial highlights, revenue breakdowns, operational updates, and management commentary on business performance. As it provides substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report (IR). H1 2014
2014-09-30 English
CK1d Update: Toxicity Results
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated September 26, 2014. It announces 'Excellent Toxicity Results' for specific compounds related to Alzheimer's disease research. The content is a press release detailing scientific progress, upcoming out-licensing strategy, and includes contact information for PR and Nominated Advisers. The presence of 'RNS Number' strongly indicates a regulatory announcement made via the London Stock Exchange's Regulatory News Service. Since this is a general announcement of positive scientific/business progress that doesn't fit the specific categories like ER (Earnings Release), DIV (Dividend), or CAP (Financing), the most appropriate general regulatory filing category is RNS.
2014-09-26 English
Contract with Genting TauRx Diagnostic Centre
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and the company name 'Proteome Sciences PLC', followed by a date (25 September 2014). The content announces a significant business event: signing a $2M contract for developing diagnostic panels. This format—a brief announcement of a material event released via the Regulatory News Service (RNS)—is characteristic of a general regulatory filing that is not a specific periodic report (like 10-K or IR) or a specific corporate action announcement (like DIV or DIRS). Since it is a general announcement disseminated through the RNS system and doesn't fit the definitions for ER, CT, CAP, etc., the most appropriate classification is the general regulatory filing category, RNS.
2014-09-25 English
Appointment of Joint Broker
Regulatory Filings Classification · 1% confidence The document is very short (1181 characters) and begins with an 'RNS Number', indicating it is a regulatory announcement from the London Stock Exchange's news service. The content announces the 'Appointment of joint broker'. This type of corporate action announcement, which is not a financial report, management change, or director dealing, fits best into the general regulatory announcement category. Since there is no specific category for 'Broker Appointment', the fallback category 'Regulatory Filings' (RNS) is the most appropriate classification, as it is explicitly sourced from RNS.
2014-08-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.